

**REMARKS**

Entry of the above amendment prior to examination is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page(s) is/are captioned "**Version With Markings to Show Changes Made.**"

**I. Amendments**

The specification is amended to format the Sequence Listing in accord with 37 C.F.R. §1.821-§1.825.

The specification is further amended in accordance with 37 C.F.R. §1.821(d) to make reference to sequences discussed in the description or claims by the sequence identifier preceded by "SEQ ID NO:".

Applicants submit that the application is now in compliance with 37 C.F.R. §1.821-§1.825.

If in the opinion of the Examiner a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 846-7500.

Respectfully submitted,

*Victoria L. Boyd*  
Victoria L. Boyd  
Registration No. 43,510

Date: 2/6/02  
Genencor International, Inc.  
925 Page Mill Road  
Palo Alto, CA 94304  
Phone: (650) 846-7615  
Fax: (650) 845-6504

USSN 09/955,555



COPY OF PAPERS  
ORIGINALLY FILED

Version with Markings to Show Chang's Mad

Figure 6. The amino acid sequence of the first (1-153) and second (154-306) internal repeating units followed by the CBD (239-531) sequence, SEQ ID NO:29. As described in Example 6, this protein was expressed in the form of GST fusion protein and was cleaved off from the GST protein moiety by the treatment of protease Factor Xa.